logo-loader
HealthPharma & Biotech
AstraZeneca

AstraZeneca reports pancreatic cancer trial success for Lynparza

Lynparza though showed significantly increased rates of survival in the phase III POLO trial

cancer
Parp-1 inhibitors stop cancer cells repairing themselves

AstraZeneca PLC (LON:AZN) has claimed the first positive result by a Parp-1 inhibitor as a treatment for one type of pancreatic cancer.

Pancreatic cancer is one of the hardest to treat as it is very hard to spot and patients often only become aware of the disease when it is too late for effective treatment.

READ: AstraZeneca rises as Brilinta medicine meets goal in Phase III clinical trial

Lynparza though showed significantly increased rates of survival in the phase III POLO trial.

José Baselga, Astra's head of oncology research, said: "This is the first positive Phase III trial of any PARP inhibitor in germline BRCA-mutated metastatic pancreatic cancer, a devastating disease with critical unmet need.

Parp-1 inhibitors stop cancer cells repairing themselves while BRCA-1 and -2 genes are the body's tumour suppressants and mutations of these can significantly increase the risk of occurrence.

"The results of POLO provide further evidence of the clinical benefit of Lynparza across a variety of BRCA-mutated tumour types. We will discuss these results with global health authorities as soon as possible," added Baselga.

Lynparza is being developed jointly by Astra and US group Merck.

"The clinically-meaningful results of this trial potentially support the value of testing for germline BRCA mutations in patients with metastatic pancreatic cancer," said Roy Baynes, Merck's head of global clinical development.

Quick facts: AstraZeneca

Price: £68.48

Market: LSE
Market Cap: £900.61 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Clear Leisure CEO confident of a positive outcome to its litigation issues

Francesco Gardin, chief executive and executive chairman of Clear Leisure PLC (LON:CLP), updates Proactive London on the firm's investments and ongoing litigation cases. This week the company's subsidiary, Clear Leisure 2017, agreed with Sipiem to buy the €10.8m legal action against the...

2 days, 5 hours ago

2 min read